Market Data
Market Cap₹19.32 Cr.
52W High₹87.91
Current Price₹76.69
52W Low₹36.11
Down from 52W High12.8 %
Face Value₹10
Performance
ROCE33.37 %
ROE27.79 %
EPS (TTM)₹9.53
EPS Prev Qtr₹0.68
EPS Last Year₹0.56
EBITDA Qtr₹0.02 Cr.
Book Value₹40
Financial Health
Debt/Equity0.04
Debt/Profit0.14
Total Assets₹12.78 Cr.
Promoter Holding50.6 %
Earning Power1.33 %
Valuation
Stock P/E6.91
Industry P/E32.65
Price to Book1.92
Price to Sales3.33
Graham Number₹99.88
Key Metrics
Face Value
₹10
About Colinz Laboratories Ltd
Healthcare · Pharmaceuticals
Colinz Laboratories Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹19.32 Cr.
Price Chart
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.11 | ₹4,36,678.96 Cr | 0.88% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 84.22 | ₹2,46,407.94 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 76.59 | ₹1,82,633.63 Cr | 0.79% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 25.93 | ₹1,16,044.61 Cr | 0.09% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 32.34 | ₹1,09,059.12 Cr | 0.96% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 97.81 | ₹1,07,055.86 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 50.62 | ₹1,03,455.49 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 31.95 | ₹1,03,165.93 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.04 | ₹95,886.73 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.48 | ₹93,366.88 Cr | 0.88% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.26 | ₹65,185.56 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.52 | ₹61,528.15 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 109.12 | ₹60,461.65 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.73 | ₹57,690.58 Cr | 1.75% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Ipca Laboratories Ltd | - | 36.26 | ₹48,896.41 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.64 | ₹48,298.98 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.39 | ₹47,904.29 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.63 | ₹46,884.81 Cr | 2.06% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.82 | ₹45,194.84 Cr | 0.77% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 1.39 | 1.43 | 1.75 | 1.24 |
| ↳ QoQ Growth | - | +2.9% | +22.4% | -29.1% |
| Expenses | 1.35 | 1.37 | 1.7 | 1.22 |
| Operating Profit | 0.04 | 0.06 | 0.05 | 0.02 |
| OPM % | 2.88% | 4.2% | 2.86% | 1.61% |
| Other Income | 0.16 | 0.08 | 0.17 | 0.12 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.04 |
| EBITDA | 0.08 | 0.1 | 0.09 | 0.06 |
| EBITDA Margin % | 5.76% | 6.99% | 5.14% | 4.84% |
| Profit Before Tax | 0.19 | 0.13 | 0.22 | 2.9 |
| Tax % | 26.32% | 30.77% | 18.18% | 17.24% |
| Net Profit | 0.14 | 0.08 | 0.17 | 2.4 |
| ↳ QoQ Growth | - | -42.9% | +112.5% | +1311.8% |
| EPS | 0.56 | 0.33 | 0.68 | 9.53 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 2.5191 | 2.52 |
| Reserves | 6.9553 | 7.52 |
| Borrowings | 0.64 | 0.39 |
| Other Liabilities | 1.7 | 2.35 |
| Total Liabilities | 11.8174 | 12.78 |
| Fixed Assets | 1.7005 | 1.54 |
| CWIP | 0 | 0 |
| Investments | 1.04 | 1.11 |
| Other Assets | 9.08 | 10.13 |
| Total Assets | 11.8174 | 12.78 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | -1.4537 |
| Cash from Investing Activity | -0.2343 |
| Cash from Financing Activity | 0.238 |
| Net Cash Flow | -1.45 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 66% | 66% | 66% | 50.6% |
| FIIs % | 0% | 0% | 0% | 0% |
| DIIs % | 0% | 0% | 0% | 0% |
| Public % | 30.97% | 31.01% | 31.22% | 46.19% |
| No. of Shareholders | 3,272 | 3,212 | 3,250 | 3,174 |